Literature DB >> 3264265

Delayed type hypersensitivity (DTH) in anti-IgM-treated B cell-depleted mice: analysis of induction and effector phase.

P Herrmann1, M H Schreier, H Bazin, R M Zinkernagel, A Cerny.   

Abstract

The induction and the effector phase of murine delayed type hypersensitivity (DTH) were evaluated in mice treated from birth with anti-IgM antibodies; these mice had no mature B cells and could not produce an antibody response. To study the effector phase, long-term cultured cloned helper T cells were injected subcutaneously together with the specific antigen into the hind footpad of normal and B cell-deficient mice. Antigen-specific DTH responses assessed by the local swelling reaction 24 h after transfer measured against a particulate antigen (sheep red blood cells, SRBC) as well as a soluble antigen (ovalbumin, OVA) were unaffected by the absence of B cells. To study the induction phase of DTH, 3-day immune in vivo primed lymphocytes from normal or B cell-depleted mice were adoptively transferred by subcutaneous injection into the hind footpad of naive syngeneic recipients. B cell depletion did not affect the induction of cells capable of responding to SRBC; in contrast, the response to soluble antigen (OVA) was significantly reduced, suggesting that B cells or their products participated in the induction of a DTH response to a soluble antigen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264265     DOI: 10.1016/S0171-2985(88)80006-8

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  1 in total

1.  Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Authors:  Nancy L Monson; Petra Cravens; Rehana Hussain; Christopher T Harp; Matthew Cummings; Maria de Pilar Martin; Li-Hong Ben; Julie Do; Jeri-Anne Lyons; Amy Lovette-Racke; Anne H Cross; Michael K Racke; Olaf Stüve; Mark Shlomchik; Todd N Eagar
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.